1932

Abstract

Chronic hepatitis B virus (HBV) infection impacts an estimated 257–291 million people globally. The current approach to treatment for chronic HBV infection is complex, reflecting a risk:benefit approach driven by the lack of an effective curative regimen. This complexity and the lack of a durable treatment response, necessitating indefinite treatment in the majority of cases, have resulted in low uptake of testing and treatment, particularly in regions where comprehensive primary care is lacking and access to affordable testing and treatment is limited. Multiple targeted therapies are now in early human study with the primary goal to achieve persistent HBV DNA and hepatitis B surface antigen suppression after a finite course of treatment, which is referred to as functional cure. This article summarizes the current therapies for HBV infection and discusses the limitations of these therapies, novel approaches to HBV cure, and therapeutic endpoints of clinical trials aimed to cure hepatitis B.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-080119-103356
2021-01-27
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/med/72/1/annurev-med-080119-103356.html?itemId=/content/journals/10.1146/annurev-med-080119-103356&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    WHO (World Health Organ.) 2017. Global hepatitis report Rep., WHO, Geneva Switz: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
  2. 2. 
    Polaris Obs. Collab 2018. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol. Hepatol. 3:6383–403
    [Google Scholar]
  3. 3. 
    Schweitzer A, Horn J, Mikolajczyk RT et al. 2015. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386:1546–55
    [Google Scholar]
  4. 4. 
    Foreman KJ, Marquez N, Dolgert A et al. 2018. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 392:2052–90
    [Google Scholar]
  5. 5. 
    Terrault NA, Lok ASF, McMahon BJ et al. 2018. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67:1560–99
    [Google Scholar]
  6. 6. 
    Dore GJ, Feld JJ, Thompson A et al. 2020. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. J. Hepatol. 72:431–40
    [Google Scholar]
  7. 7. 
    Gupta N, Mbituyumuremyi A, Kabahizi J et al. 2019. Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. Lancet Gastroenterol. Hepatol. 4:119–26
    [Google Scholar]
  8. 8. 
    Naggie S, Muir AJ. 2017. Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs. Annu. Rev. Med. 68:345–58
    [Google Scholar]
  9. 9. 
    Seitz S, Urban S, Antoni C, Böttcher B 2007. Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions. EMBO J 26:4160–67
    [Google Scholar]
  10. 10. 
    Sureau C, Salisse J. 2013. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus A-determinant. Hepatology 57:985–94
    [Google Scholar]
  11. 11. 
    Yan H, Zhong G, Xu G et al. 2012. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1:e00049
    [Google Scholar]
  12. 12. 
    Schreiner S, Nassal M. 2017. A role for the host DNA damage response in hepatitis B virus cccDNA formation—and beyond. Viruses 9:125
    [Google Scholar]
  13. 13. 
    Marcellin P, Gane E, Buti M et al. 2013. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381:468–75
    [Google Scholar]
  14. 14. 
    Ahn SH, Park YN, Park JY et al. 2005. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J. Hepatol. 42:188–94
    [Google Scholar]
  15. 15. 
    Liu J, Yang HI, Lee MH et al. 2014. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut 63:1648–57
    [Google Scholar]
  16. 16. 
    Simonetti J, Bulkow L, McMahon BJ et al. 2010. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 51:1531–37
    [Google Scholar]
  17. 17. 
    Lai CL, Yuen MF. 2013. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 57:399–408
    [Google Scholar]
  18. 18. 
    Liaw YF, Sung JJ, Chow WC et al. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351:1521–31
    [Google Scholar]
  19. 19. 
    Yuen MF, Chen DS, Dusheiko GM et al. 2018. Hepatitis B virus infection. Nat. Rev. Dis. Primers 4:18035
    [Google Scholar]
  20. 20. 
    Kim GA, Lim YS, An J et al. 2014. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 63:1325–32
    [Google Scholar]
  21. 21. 
    Yuen MF, Wong DK, Fung J et al. 2008. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 135:1192–99
    [Google Scholar]
  22. 22. 
    Yip TC, Wong GL, Chan HL et al. 2019. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J. Hepatol. 70:361–70
    [Google Scholar]
  23. 23. 
    Cornberg M, Lok AS, Terrault NA, Zoulim F 2020. Guidance for design and endpoints of clinical trials in chronic hepatitis B—report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. J. Hepatol. 72:539–57
    [Google Scholar]
  24. 24. 
    Chan HL, Thompson A, Martinot-Peignoux M et al. 2011. Hepatitis B surface antigen quantification: why and how to use it in 2011—a core group report. J. Hepatol. 55:1121–31
    [Google Scholar]
  25. 25. 
    Yip TC, Lok AS. 2020. How do we determine whether a functional cure for HBV infection has been achieved. Clin. Gastroenterol. Hepatol. 18:548–50
    [Google Scholar]
  26. 26. 
    Cornberg M, Wong VW, Locarnini S et al. 2017. The role of quantitative hepatitis B surface antigen revisited. J. Hepatol. 66:398–411
    [Google Scholar]
  27. 27. 
    Liu Y, Jiang M, Xue J et al. 2019. Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection. BMC Gastroenterol 19:53
    [Google Scholar]
  28. 28. 
    Giersch K, Allweiss L, Volz T et al. 2017. Serum HBV pgRNA as a clinical marker for cccDNA activity. J. Hepatol. 66:460–62
    [Google Scholar]
  29. 29. 
    Wang J, Shen T, Huang X et al. 2016. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J. Hepatol. 65:700–10
    [Google Scholar]
  30. 30. 
    Seto WK, Wong DK, Fung J et al. 2014. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clin. Microbiol. Infect. 20:1173–80
    [Google Scholar]
  31. 31. 
    Testoni B, Lebossé F, Scholtes C et al. 2019. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J. Hepatol. 70:615–25
    [Google Scholar]
  32. 32. 
    Suzuki F, Miyakoshi H, Kobayashi M, Kumada H 2009. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J. Med. Virol. 81:27–33
    [Google Scholar]
  33. 33. 
    Bogomolov P, Alexandrov A, Voronkova N et al. 2016. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J. Hepatol. 65:490–98
    [Google Scholar]
  34. 34. 
    Zoulim F, Lenz O, Vandenbossche JJ et al. 2020. JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection. Gastroenterology 159:2521–33
    [Google Scholar]
  35. 35. 
    Yuen M. 2019. First clinical experience with RNA interference [RNAi]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989, JNJ-56136379 and a nucleos(t)ide analogue (NA) Paper presented at the American Association for the Study of Liver Diseases Annual Meeting Nov. 8–12 Boston, MA:
  36. 36. 
    Ma X, Lalezari J, Nguyen T et al. 2019. Interim safety and efficacy results of the ABI‐H0731 phase 2a program exploring the combination of ABI‐H0731 with Nuc therapy in treatment‐naive and treatment‐suppressed chronic hepatitis B patients Paper presented at the International Liver Congress Apr 10–14 Vienna, Austria:
  37. 37. 
    Sulkowski M. 2019. Continued therapy with ABI-H0731+Nrtl results in sequential reduction/loss of HBV DNA, HBV RNA, HBeAg, HBcrAg and HBsAg in HBeAg-positive patients Paper presented at the American Association for the Study of Liver Diseases Annual Meeting Nov 8–12 Boston, MA:
  38. 38. 
    Wooddell CI, Yuen MF, Chan HL et al. 2017. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci. Transl. Med. 9:eaan0241
    [Google Scholar]
  39. 39. 
    Gane E, Locarnini SA, Lim TH et al. 2018. First results with RNA interference (RNAi) in chronic hepatitis B (CHB) using ARO‐HBV Paper presented at the American Association for the Study of Liver Diseases Annual Meeting Nov 9–13 San Francisco, CA:
  40. 40. 
    Bazinet M, Pântea V, Cebotarescu V et al. 2017. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 2:877–89
    [Google Scholar]
  41. 41. 
    Bazinet M, Pântea V, Placinta G et al. 2020. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy. Gastroenterology 158:2180–94
    [Google Scholar]
  42. 42. 
    Finter NB, Chapman S, Dowd P et al. 1991. The use of interferon-α in virus infections. Drugs 42:749–65
    [Google Scholar]
  43. 43. 
    McHutchison JG, Lawitz EJ, Shiffman ML et al. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361:580–93
    [Google Scholar]
  44. 44. 
    Xie Q-L, Zhu Y, Wu L-H et al. 2015. The efficacy and safety of entecavir and interferon combination therapy for chronic hepatitis B virus infection: a meta-analysis. PLOS ONE 10:e0132219
    [Google Scholar]
  45. 45. 
    Isorce N, Lucifora J, Zoulim F, Durantel D 2015. Immune-modulators to combat hepatitis B virus infection: from IFN-α to novel investigational immunotherapeutic strategies. Antivir. Res. 122:69–81
    [Google Scholar]
  46. 46. 
    Ma Z, Cao Q, Xiong Y et al. 2018. Interaction between hepatitis B virus and Toll-like receptors: current status and potential therapeutic use for chronic hepatitis B. Vaccines 6:6
    [Google Scholar]
  47. 47. 
    Lanford RE, Guerra B, Chavez D et al. 2013. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144:1508–17, 1517.e1–10
    [Google Scholar]
  48. 48. 
    Menne S, Tumas DB, Liu KH et al. 2015. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. J. Hepatol. 62:1237–45
    [Google Scholar]
  49. 49. 
    Gane EJ, Lim YS, Gordon SC et al. 2015. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J. Hepatol. 63:320–28
    [Google Scholar]
  50. 50. 
    Janssen HLA, Brunetto MR, Kim YJ et al. 2018. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. J. Hepatol. 68:431–40
    [Google Scholar]
  51. 51. 
    Mackman RL, Mish M, Chin G et al. 2020. Discovery of GS-9688 (selgantolimod), as a potent and selective oral Toll-like receptor 8 agonist for the treatment of chronic hepatitis B. J. Med. Chem. 63:1810188–203
    [Google Scholar]
  52. 52. 
    Pardoll DM. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12:252–64
    [Google Scholar]
  53. 53. 
    Bengsch B, Martin B, Thimme R 2014. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J. Hepatol. 61:1212–19
    [Google Scholar]
  54. 54. 
    Lim SG, Agcaoili J, De Souza NNA, Chan E 2019. Therapeutic vaccination for chronic hepatitis B: a systematic review and meta-analysis. J. Viral Hepat. 26:803–17
    [Google Scholar]
/content/journals/10.1146/annurev-med-080119-103356
Loading
/content/journals/10.1146/annurev-med-080119-103356
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error